Health and Fitness Health and Fitness
Thu, May 26, 2011
[ 05:00 AM ] - Market Wire
Pro-Pharmaceuticals to Hold Conference Call to Pr .. llowing Companya?s Annual Meeting of Stockholders
[ 04:30 AM ] - Market Wire
Akorn Announces Pricing of $100 Million of Convertible Senior Notes Due 2016
[ 03:45 AM ] - Market Wire
BioCryst Presents New Analyses of BCX4208 Phase 2 .. t at the Annual European Congress of Rheumatology
[ 03:30 AM ] - Market Wire
ImmunoGen, Inc. Announces Clinical Presentations at the ASCO 2011 Annual Meeting
[ 02:45 AM ] - Market Wire
Healthways Signs Services Agreement with HP to Support Company Growth
[ 01:04 AM ] - Market Wire
Sequenom Announces Participation at Jefferies 2011 Global Healthcare Conference
[ 12:40 AM ] - Market Wire
OncoSec Medical to Initiate Multiple Phase II Skin Cancer Clinical Trials
Wed, May 25, 2011
[ 06:15 PM ] - Market Wire
Anacor Pharmaceuticals Announces Retirement of Zhi Hong from Board of Directors
[ 05:21 PM ] - Market Wire
Northwest Biotherapeutics Further Expands Ongoing Brain Cancer Trial
[ 04:19 PM ] - Market Wire
ONE Bio Announces Video Tour of Operations and Interview With Management
[ 01:34 PM ] - Market Wire
NUVO RESEARCH TO PRESENT AT BIOFINANCE 2011
[ 01:30 PM ] - Market Wire
AMAG Pharmaceuticals Announces Resignation of Chief Financial Officer
[ 01:05 PM ] - Market Wire
Neoprobe Announces Sale of Gamma Detection Device Business to Devicor Medical Products
[ 11:38 AM ] - Market Wire
STERIS Corporation to Present at the Jefferies Global Healthcare Conference on June 7, 2011
[ 09:51 AM ] - Market Wire
The Law Firm of Levi & Korsinsky, LLP Launches an .. Breaches of Fiduciary Duty by the Board of PHC, I
[ 09:32 AM ] - Market Wire
Aetna Ranked Tops in Connecting with Doctors
[ 06:53 AM ] - Market Wire
Biogen Idec begeht Welt MS Tag
[ 06:45 AM ] - Market Wire
Biogen Idec viert Wereld MS-dag
[ 06:25 AM ] - Market Wire
BioCryst Pharmaceuticals Announces Appointment of Thomas Staab as Its Next Chief Financial Officer
[ 05:30 AM ] - Market Wire
InSite Vision Receives Special Protocol Assessmen .. Phase 3 Clinical Trial of AzaSite Plusa" and Dex
[ 05:00 AM ] - Market Wire
Synovis Life Technologies Reports 49 Percent Incr .. in Operating Income in Fiscal 2011 Second Quarter
[ 05:00 AM ] - Market Wire
International Stem Cell Corporation Reports First .. ion on Strong Initial Sales of Skin Care Products
[ 05:00 AM ] - Market Wire
Angeion Announces CEO Departure and Names Interim CEO
[ 05:00 AM ] - Market Wire
St. Jude Medical to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference
[ 04:49 AM ] - Market Wire
Biogen Idec celebra el da mundial de la esclerosis mltiple
[ 04:30 AM ] - Market Wire
Akorn Announces Proposed Offering of $100 Million of Convertible Senior Notes Due 2016
[ 04:30 AM ] - Market Wire
POZEN Ranked as Second Most Efficient Pharma Company by SmarTrend
[ 04:30 AM ] - Market Wire
Medical Action Industries Reports Fourth Quarter and Fiscal 2011 Results
[ 04:00 AM ] - Market Wire
UnitedHealth Group Board Increases Shareholder Di .. idend; Renews, Increases Share Repurchase Program
[ 04:00 AM ] - Market Wire
Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference

Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference


Published on 2011-05-25 04:25:26 - Market Wire
  Print publication without navigation


ROCKVILLE, Md.--([ BUSINESS WIRE ])--Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Jefferies 2011 Global Healthcare Conference in New York on Tuesday, June 7, 2011 at 1:15 PM Eastern. During the presentation, a member of the companya™s senior management team will provide a corporate overview, which may include a discussion of the companya™s business activities and financial performance.

A webcast of this presentation will be available both live and by replay, accessible from the Emergent website [ www.emergentbiosolutions.com ] under aInvestorsa.

About Emergent BioSolutions Inc.

Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders. Additional information about the company may be found at [ www.emergentbiosolutions.com ].

Contributing Sources